Hickman, M. A., S. R. Cox, et al. (2008). "Safety, pharmacokinetics and use of the novel NK-1 receptor antagonist maropitant (Cerenia) for the prevention of emesis and motion sickness in cats." Journal of Veterinary Pharmacology and Therapeutics 31(3): 220-229.
Maropitant (Cerenia, Pfizer Animal Health) is a selective NK-1 receptor antagonist that has anti-emetic effects. It is licensed for oral use in dogs in the United States. In this study, maropitant was administered to cats at doses ranging from 0.5 to 5.0 mg/kg subcutaneously (SC) for 15 days. No adverse effects were found at any dose, including doses that exceed the anti-emetic dose by a factor of 10. The pharmacokinetics of maropitant were determined following single dose oral, intravenous, and SC administration. Anti-emesis efficacy was determined against xylazine or motion. A dosage of 1 mg/kg maropitant administered IV, SC or PO prevented emesis elicited by xylazine. The results indicate that maropitant is an effective, well tolerated and safe anti-emetic in cats at a dose of 1.0 mg/kg with a 24-hour duration of action.
>> PubMed abstractRelated articles:
de la Puente-Redondo, V. A., E. M. Siedek, et al. (2007). "The anti-emetic efficacy of maropitant (Cerenia) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe." J Small Anim Pract 48(2): 93-8.
>> PubMed abstract